12:00 AM
 | 
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MA09-hRPE cells: Phase I/II ongoing

Advanced Cell said a DSMB recommended dosing in the second dose cohort of an open-label, dose-escalation, U.K. Phase I/II trial of MA09-hRPE cells based on a review of safety data....

Read the full 129 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >